Loading...

AdAlta Limited

1AD.AXASX
Healthcare
Biotechnology
A$0.005
A$0.001(25.00%)

AdAlta Limited (1AD.AX) Financial Performance & Income Statement Overview

Review AdAlta Limited (1AD.AX) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.

Revenue Growth
-49.91%
49.91%
Operating Income Growth
36.91%
36.91%
Net Income Growth
-10.93%
10.93%
Operating Cash Flow Growth
-2.49%
2.49%
Operating Margin
-492.79%
492.79%
Gross Margin
78.23%
78.23%
Net Profit Margin
-508.01%
508.01%
ROE
-464.18%
464.18%
ROIC
-291.51%
291.51%

AdAlta Limited (1AD.AX) Income Statement & Financial Overview

Analyze AdAlta Limited’s 1AD.AX earnings with segmented quarterly and yearly financial statement figures.

MetricQ2 2025Q4 2024Q2 2024Q4 2023
Revenue$375086.00$597934.00$1.14M$2.36M
Cost of Revenue$99396.00$112447.00$9978.00$14867.00
Gross Profit$275690.00$485487.00$1.13M$2.34M
Gross Profit Ratio$0.74$0.81$0.99$0.99
R&D Expenses$887281.00$2.13M$2.03M$2.24M
SG&A Expenses$1.86M$677115.00$2.05M$2.18M
Operating Expenses$2.74M$2.81M$4.08M$4.42M
Total Costs & Expenses$2.84M$2.92M$4.09M$4.44M
Interest Income$0.00$13380.00$33345.00$34763.00
Interest Expense$0.00$42046.00$72953.00$74106.00
Depreciation & Amortization$70570.00$11883.00$9978.00$14867.00
EBITDA-$2.47M-$2.37M-$2.94M-$4.42M
EBITDA Ratio-$6.58-$3.96-$2.58-$1.87
Operating Income-$2.47M-$2.33M-$4.09M-$4.44M
Operating Income Ratio-$6.58-$3.89-$3.58-$1.88
Other Income/Expenses (Net)-$468406.00-$671637.00-$35995.00$18412.00
Income Before Tax-$2.94M-$3.00M-$4.12M-$4.42M
Income Before Tax Ratio-$7.83-$5.01-$3.62-$1.87
Income Tax Expense-$360643.00-$631279.00-$1.11M-$2.39M
Net Income-$2.58M-$2.37M-$3.01M-$2.03M
Net Income Ratio-$6.87-$3.96-$2.64-$0.86
EPS-$0.004-$0.004-$0.007-$0.006
Diluted EPS-$0.004-$0.004-$0.007-$0.006
Weighted Avg Shares Outstanding$610.38M$529.09M$454.20M$324.18M
Weighted Avg Shares Outstanding (Diluted)$610.25M$535.00M$454.20M$324.18M

Over the last four quarters, AdAlta Limited achieved steady financial progress, growing revenue from $2.36M in Q4 2023 to $375086.00 in Q2 2025. Gross profit stayed firm with margins at 74% in Q2 2025 versus 99% in Q4 2023. Operating income totaled -$2.47M in Q2 2025, maintaining a -658% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$2.47M. Net income dropped to -$2.58M, with EPS at -$0.004. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;